UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Ultrahigh-performance integrated inverters based on amorphous zinc tin oxide deposited at room temperature

APL materials, 2020-09, Vol.8 (9), p.091111-091111-8

2020

Link zum Volltext

Verfügbarkeit prüfen

Mechanical Stress Stability of Flexible Amorphous Zinc Tin Oxide Thin-Film Transistors

Frontiers in electronics (Online), 2021-12, Vol.2

2021

Link zum Volltext

Verfügbarkeit prüfen

Ahead of the Curve: Innovative Cold Bent Insulated Glass Entry Wall

Challenging glass conference proceedings, 2018, Vol.6 (1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Full-Swing, High-Gain Inverters Based on ZnSnO JFETs and MESFETs

IEEE transactions on electron devices, 2019-08, Vol.66 (8), p.3376-3381

2019

Link zum Volltext
Volltext

All‐Oxide Transparent Thin‐Film Transistors Based on Amorphous Zinc Tin Oxide Fabricated at Room Temperature: Approaching the Thermodynamic Limit of the Subthreshold Swing

Advanced electronic materials, 2020-10, Vol.6 (10), p.n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Low‐Voltage Operation of Ring Oscillators Based on Room‐Temperature‐Deposited Amorphous Zinc‐Tin‐Oxide Channel MESFETs

Advanced electronic materials, 2019-12, Vol.5 (12), p.n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.661-671

2017

Link zum Volltext

Verfügbarkeit prüfen

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Translational oncology, 2021-02, Vol.14 (2), p.100984-100984, Article 100984

2021

Link zum Volltext

Verfügbarkeit prüfen

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e17042-e17042

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-07, Vol.17 (7), p.1007-1015

2015

Link zum Volltext

Verfügbarkeit prüfen

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5549-5549

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2092-2092

2013

Link zum Volltext

Verfügbarkeit prüfen

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2525-2525

2014

Link zum Volltext

Verfügbarkeit prüfen

Application of 3-D visualization to integrated geophysical and geologic model building; a prestack, subsalt depth migration project, deepwater Gulf of Mexico

Leading edge (Tulsa, Okla.), 2000-05, Vol.19 (5), p.466-472

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(18)
Tagungsberichte
(1)

Sprache

Englisch
(19)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(10)
Life Sciences & Biomedicine
(5)
Technology
(5)
Humans
(4)
Oncology
(4)
Physical Sciences
(4)
Physics
(4)
Physics, Applied
(4)
Angiogenesis Inhibitors - Pharmacokinetics
(3)
Antibodies, Monoclonal - Pharmacokinetics
(3)
Bevacizumab
(3)
Cancer
(3)
Female
(3)
Male
(3)
Materials Science
(3)
Materials Science, Multidisciplinary
(3)
Nanoscience & Nanotechnology
(3)
Pharmacology
(3)
Science & Technology - Other Topics
(3)
Transparent Amorphous Oxide Semiconductors
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ultrahigh-performance integrated inverters based on amorphous zinc tin oxide deposited at room temperature

Mechanical Stress Stability of Flexible Amorphous Zinc Tin Oxide Thin-Film Transistors

Ahead of the Curve: Innovative Cold Bent Insulated Glass Entry Wall

Full-Swing, High-Gain Inverters Based on ZnSnO JFETs and MESFETs

All‐Oxide Transparent Thin‐Film Transistors Based on Amorphous Zinc Tin Oxide Fabricated at Room Temperature: Approaching the Thermodynamic Limit of the Subthreshold Swing

Low‐Voltage Operation of Ring Oscillators Based on Room‐Temperature‐Deposited Amorphous Zinc‐Tin‐Oxide Channel MESFETs

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study

Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM)

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Application of 3-D visualization to integrated geophysical and geologic model building; a prestack, subsalt depth migration project, deepwater Gulf of Mexico

Suchergebnisse filtern